Insulet Gross Profit

The latest gross profit for PODD is $2.3B as of September 2026. That compares with $1.8B in the prior-year period — up 27.2% year over year. That is below the Healthcare sector average of $4.6T. Investors often review this figure alongside Insulet's historical trend and sector peers before judging valuation or financial health.

Over the past year, PODD's gross profit moved from $1.8B to $2.3B — a 27.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Insulet's operating scale or balance-sheet position.

Against Healthcare companies, PODD currently prints $2.3B for gross profit, while the sector average sits near $4.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Insulet's growth, margins, and balance sheet.

A gross profit figure of $2.3B for PODD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $4.6T. Explore the charts below for those layers of context.

After noting PODD's gross profit ($2.3B), review year-over-year change from $1.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.